Consensus recommendations of the working group on pulmonary arterial hypertension of the Austrian Society for Lung Diseases and Tuberculosis;Konsensus-empfehlungen der arbeitsgruppe pulmonalarterielle hypertension der Österreichischen gesellschaft für lungenerkrankungen und tuberkulose

Wiener Klinische Wochenschrift

Volumn 115, Issue 10, 2003, Pages 351-365

  Ziesche, Rolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Consensus; Pulmonary hypertension

Indexed keywords

AMINOREX; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; BERAPROST; BOSENTAN; COCAINE; DIHYDRALAZINE; DILTIAZEM; FENFLURAMINE; ILOPROST; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; PHENTERMINE; PROSTACYCLIN; SILDENAFIL; TRYPTOPHAN; UNIPROST; URAPIDIL; VASOACTIVE INTESTINAL POLYPEPTIDE;

AUSTRIA; CONFERENCE PAPER; DISEASE CLASSIFICATION; HUMAN; LIVER TOXICITY; LUNG DISEASE; LUNG TUBERCULOSIS; MEDICAL SOCIETY; PULMONARY HYPERTENSION; RISK FACTOR; TREATMENT INDICATION;

EID: 0037863330     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03041488     Document Type: Conference Paper

References (54)

1. Welty-Wolf KE, Carraway MS, Miller DL, Ortel TL, Ezban M, Ghio AJ, Idell S, Piantadosi CA (2001) Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 164: 1988-1996
2. Voelkel NF, Cool C, Taraceviene SL, G MW, Yeager M, Bull T, Kasper M, Tuder RM (2002) Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit Care Med 30: S251-256
3. Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, Alger LA, Narumiya S, Geraci MW (2001) Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med 164: 314-318
4. Berger RM, Geiger R, Hess J, Bogers AJ, Mooi WJ (2001) Altered arterial expression patterns of inducible and endothelial nitric oxide synthase in pulmonary plexogenic arteriopathy caused by congenital heart disease. Am J Respir Crit Care Med 163: 1493-1499
5. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732-1739
6. Yuan XJ, Wang J, Juhaszova M, Gaine SP, Rubin LJ (1998) Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 351 (9104): 726-727
7. Cowan KN, Jones PL, Rabinovitch M (2000) Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 105: 21-34
8. Zaidi SHE, You XM, Ciura SM, Husain M, Rabinovitch M (2002) Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 105: 516-521
9. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M (2000) Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 6: 698-702
10. Newman JH, Wheeler L, Lane KB, Loyd E, Gaddipati R, Phillips JA 3rd, Loyd JE (2001) Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 345: 319-324
11. Morse JH, Deng Z, Knowles JA (2001) Genetic aspects of pulmonary arterial hypertension. Ann Med 33: 596-603
12. Geraci MW, Moore M, Gesell T, Yeager ME, Alger L, Golpon H, Gao B, Loyd JE, Tuder RM, Voelkel NF (2001) Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res 88: 555-562
13. Du L, Sullivan CC, Chu D, Cho AJ, Kido M, Wolf PL, Yuan JX, Deutsch R, Jamieson SW, Thistlethaite PA (2003) Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 348: 500-509
14. Rich S (ed) (1998) Executive summary from the World Symposium on Primary pulmonary Hypertension, Evian, France, co-sponsered by the World Health Organisation. (http:/www.who.int/cvd/pph/html)
15. Sun XG, Hansen JE, Oudiz RJ, Wasserman K (2003) Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 41: 1028-1035
16. Ziesche R, Petkov V, Wittmann K, Kopatschka J, Stiebellehner L, Schenk P, Germann P, Röder G, Ullrich R, Block LH (2000) Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension. Heart 83: 406-409
17. Higenbottam T, Wheeldon D, Wells F, Wallwork J (1984) Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet i (8385): 1046-1047
18. Hantano S, Strasser T (eds) (1975) Primary pulmonary hypertension. Report on the WHO Meeting. World Health Organisation, Geneva. In: Higenbottam TW (ed) Therapy for patients with pulmonary vascular disease. N Engl J Med 306: 557-564
19. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kemis JT, et al (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115: 343-349
20. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL (1984) Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70: 580-587
21. Jones DK, Higenbottam TW, Wallwork J (1987) Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). British Heart Journal 57: 270-278
22. Higenbottam T (1987) The place of prostacyclin in the clinical management of primary pulmonary hypertension. Am Rev Resp Dis 136: 782-785
23. Jones K, Higenbottam T, Wallwork J (1989) Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. Chest 96: 784-789
24. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE (1982) Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 66: 334-338
25. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al (1990) Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112: 485-491
26. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS (1994) Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121: 409-415
27. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L (1998) Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 80: 151-155
28. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296-302
29. McLaughlin VV, Genthner DE, Panella MM, Rich S (1998) Reduction in pulmonary vascular resistance with long-term epoprostenol prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338: 273-277
30. Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D, Mandayam S, Ginzton LE, Brundage BH (1997) Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 30: 343-349
31. Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336: 111-117
32. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W (1996) Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124: 820-824
33. Wensel R, Opitz CF, Ewert R, Bruch L, Kleber FX (2000) Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation 101: 2388-2392
34. Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Hoeper MM, Behr J, Kleber FX, Seeger W (2000) Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. Ann Intern Med 132: 435-443
35. Hoeper MM, Schwarze M, Ehlerding S, Adler Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H (2000) Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342: 1866-1870
36. Machherndl S, Kneussl M, Baumgartner H, Schneider B, Petkov V, Schenk P, Lang IM (2001) Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur Respir J 17: 8-13
37. Olschewski H, Simonneau G, Galie N, Higenbottam T, et al, for the Aerosolized Iloprost Randomized Study Group (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347: 322-329
38. Simmoneau G, Barst RJ, Galiè N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ, for the Treprostinil Study Group (2002) Continuous subcutaneous infusion of Treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165: 800-804
39. Galiè N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoeper M, Chaouat A, Morand S, Besse B, Simmoneau G for the Arterial Pulmonary Hypertension and Beraprost European Trial (ALPHABET) Study Group (2002) Effect of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind, placebo-controlled trial. J Am Coll Card 39: 1496-1502
40. Channick RN, Simonneau G, Sitbon O, Robbins I, Frost A, Tapson VF, Badesch DB, Roux S, Raisinio M, Bodin F, et al (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358: 1119-1123
41. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al (2002) Bosentan in patients with pulmonary artery hypertension: a randomized, placebo controlled, multicenter study. N Engl J Med 346: 896-903
42. Palevsky HI, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E, et al (1989) Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 80: 1207-1221
43. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calciumchannel blockers in primary pulmonary hypertension. Eur Respir J 12: 265-270
44. Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327: 76-81
45. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL (1984) Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70: 580-587
46. Reitz BA, Wallwork JL, Hunt SA, Pennock JL, Billingham ME, Oyer PE, Stinson EB, Shumway NE (1982) Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 306: 557-564
47. Tamm M, Sharples LD, Higenbottam TW, Stewart S, Wallwork J (1997) Bronchiolitis obliterans syndrome in heart-lung transplantation - surveillance biopsies. Am J Respir Crit Care Med 155: 1705-1710
48. Keck BM, Bennett LE, Fiol BS, Daily OP, Novick RJ, Hosenpud JD (1998) Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. Clin Transplant: 39-52
49. Meyers BF, Lynch J, Trulock EP, Guthrie TJ, Cooper JD, Patterson GA (1999) Lung transplantation: a decade of experience. Ann Surg 230: 362-370
50. The American Society for Transplant Physicians (ASTP)/American Thoracic Society (ATS)/European Respiratory Society (ERS)/International Society for Heart and Lung Transplantation (ISHLT) (1998) International guidelines for the selection of lung transplant candidates. Am J Respir Crit Care Med 158: 335-339
51. Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ (1995) Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 91: 2028-2035
52. Rich S, Dodin E, McLaughlin VV (1997) Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. Am J Cardiol 80: 369-371
53. Sandoval J, Gaspar J, Pulido T, Bautista E, Martinez GM, Zeballos M, et al (1998) Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 32: 297-304
54. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, Block LH (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111: 1339-1346